2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH FRED SAAD
Delaying Disease Progression in Early Nonmetastatic CRPC Treatment

VIEW ALL ASCO GU 2019 VIDEOS

Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH ALAN BRYCE
Results from TRITON2: Treatment of mCRPC with Rucaparib

VIEW ALL PCF VIDEOS

European Society for Medical Oncology 2018 Congress

European Society for Medical Oncology 2018 Congress

PANEL DISCUSSION
Current Management of Bone Metastatic Castrate-Resistant Prostate Cancer

VIEW ALL ESMO VIDEOS

European Society for Medical Oncology 2018 Congress

 European Society for Medical Oncology 2018 Congress

INTERVIEW WITH ARJUN BALAR
Immunotherapy in Bladder Cancer

VIEW ALL ESMO VIDEOS


Notice: Trying to get property of non-object in /home/urotoday/public_html/templates/t3_bs3_blank/html/mod_media_media/carousel-featured.php on line 18
Featured Videos

Ten-year experience with multimodal treatment for acute phase Peyronie's disease: A real life clinical report.

To present our experience with multimodal therapy for Peyronie's disease.

Retrospective data were collected since 2008 to 2017. The following features were evaluated at baseline and after treatment: age, duration of disease, erectile function, erected penile curvature, and stretched penile length. All patients were offered the same protocol including: 12 intralesional verapamil injections, oral therapy (OT) ?L-arginine 2g once and pentoxifylline 400mg 3 times a day for 6 months?, and penile traction therapy. The adherence to each of the 3 components of multimodal treatment was evaluated.

One hundred and seventy-seven individuals were considered. Depending on the grade of adherence our survey was divided into 3 groups. Group 1: patients who only completed OT; group 2: men who accomplished OT and intralesional verapamil injections; group 3: patients who completed the entire protocol. Seventy-six, 45 and 56 men were assigned to group 1, 2 and 3 respectively. The mean age at the diagnosis was 59±8.4, 59.1±5.9 and 54.2±4.8 years, while the mean duration of the disease was 6.3±3.4, 4.8±2.9 and 3.9±3.1 months in group 1, 2 and 3. The erected penile curvature before and after treatment was 24.2±9 and 23.7±8.9° in group 1 (P<.36); 25.4±16.8 and 24.1±13.6° in group 2 (P<.34), and 34.3±17.9 and 26.1±17.2° in group 3 (P<.001).

OT alone was successful to block the progression of the disease. The add of intralesional verapamil injections to OT brought only mild improvements. The complete protocol significantly reduced erected penile curvature and improved erectile function.

Actas urologicas espanolas. 2019 Jan 28 [Epub ahead of print]

L Gallo, P Sarnacchiaro

Gallo Uro-Andrology Centre, Nápoles, Italia. Electronic address: ., Gallo Uro-Andrology Centre, Nápoles, Italia.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe

Calendar
Upcoming educational events
March 21-22, 2019 / AUA Headquarters
Bladder Cancer in Women Research Symposium
March 28-31, 2019 / Disney's Grand Floridian Resort & Spa
51st Duke Urologic Assembly and Urologic Cancer Symposium